Collaboration and Licensing Revenue

The Company generates revenue through contractual agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensees obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Upfront and milestone payments are typically deferred and recognized over the expected life of the Company's technology platform using a straight-line approach. The Company recognizes the reimbursement payments received for research and development services in the period in which the services are performed and collection is reasonably assured. The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and six months ended June 30, 2017 and 2016.



	Three Months Ended June 30, 2017
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	4,842	$	5,122	$	9,964
Oragenics, Inc.	261		214		475
Fibrocell Science, Inc.	605		1,348		1,953
Genopaver, LLC	68		1,445		1,513
S & I Ophthalmic, LLC	—		72		72
OvaXon, LLC	—		880		880
Intrexon Energy Partners, LLC	625		1,295		1,920
Persea Bio, LLC	125		141		266
Ares Trading S.A.	1,597		1,206		2,803
Intrexon Energy Partners II, LLC	500		456		956
Intrexon T1D Partners, LLC	272		1,016		1,288
Harvest start-up entities (1)	606		3,846		4,452
Other	923		699		1,622
Total	$	10,424	$	17,740	$	28,164


(1)	For the three months ended June 30, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.



	Three Months Ended June 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	922	$	6,048	$	6,970
Oragenics, Inc.	261		246		507
Fibrocell Science, Inc.	605		789		1,394
Genopaver, LLC	68		1,569		1,637
S & I Ophthalmic, LLC	—		2,358		2,358
OvaXon, LLC	—		808		808
Intrexon Energy Partners, LLC	625		3,587		4,212
Persea Bio, LLC	125		206		331
Ares Trading S.A.	1,597		621		2,218
Intrexon Energy Partners II, LLC	500		394		894
Intrexon T1D Partners, LLC	278		32		310
Harvest start-up entities (1)	305		634		939
Other	2,769		2,134		4,903
Total	$	8,055	$	19,426	$	27,481


(1)	For the three months ended June 30, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and Relieve Genetics, Inc.



	Six Months Ended June 30, 2017
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	9,684	$	11,265	$	20,949
Oragenics, Inc.	524		520		1,044
Fibrocell Science, Inc.	1,210		2,482		3,692
Genopaver, LLC	137		3,056		3,193
S & I Ophthalmic, LLC	—		375		375
OvaXon, LLC	—		1,704		1,704
Intrexon Energy Partners, LLC	1,250		5,756		7,006
Persea Bio, LLC	250		305		555
Ares Trading S.A.	3,194		2,924		6,118
Intrexon Energy Partners II, LLC	1,000		1,105		2,105
Intrexon T1D Partners, LLC	536		1,884		2,420
Harvest start-up entities (1)	1,207		6,608		7,815
Other	2,756		1,497		4,253
Total	$	21,748	$	39,481	$	61,229


(1)	For the six months ended June 30, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.



	Six Months Ended June 30, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	1,844	$	12,107	$	13,951
Oragenics, Inc.	524		789		1,313
Fibrocell Science, Inc.	1,210		2,041		3,251
Genopaver, LLC	137		3,078		3,215
S & I Ophthalmic, LLC	—		3,544		3,544
OvaXon, LLC	—		1,502		1,502
Intrexon Energy Partners, LLC	1,250		6,950		8,200
Persea Bio, LLC	250		405		655
Ares Trading S.A.	3,194		1,429		4,623
Intrexon Energy Partners II, LLC	1,000		444		1,444
Intrexon T1D Partners, LLC	278		32		310
Harvest start-up entities (1)	351		1,022		1,373
Other	3,789		4,384		8,173
Total	$	13,827	$	37,727	$	51,554


(1)	For the six months ended June 30, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and Relieve Genetics, Inc.

There have been no significant changes to arrangements with our collaborators and licensees in the six months ended June 30, 2017. See Note 5 in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 for additional details of the Company's existing collaboration and licensing agreements.

Deferred Revenue

Deferred revenue primarily consists of consideration received for upfront and milestone payments in connection with the Company's collaborations and licensing agreements, prepayments for research and development services performed for collaborators and licensees, and prepayments for product and service revenues. Deferred revenue consists of the following:



	June 30, 2017		December 31, 2016
Upfront and milestone payments	$	278,262	$	297,867
Prepaid research and development services	2,502		6,015
Prepaid product and service revenues	4,550		5,554
Other	4		706
Total	$	285,318	$	310,142
Current portion of deferred revenue	$	47,662	$	53,364
Long-term portion of deferred revenue	237,656		256,778
Total	$	285,318	$	310,142

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement.



	June 30, 2017		December 31, 2016
ZIOPHARM Oncology, Inc.	$	129,125	$	138,809
Oragenics, Inc.	7,242		7,766
Fibrocell Science, Inc.	17,816		19,026
Genopaver, LLC	1,840		1,977
Intrexon Energy Partners, LLC	16,875		18,125
Persea Bio, LLC	3,750		4,000
Ares Trading S.A.	43,984		47,178
Intrexon Energy Partners II, LLC	14,833		15,833
Intrexon T1D Partners, LLC	8,678		8,653
Harvest start-up entities (1)	19,400		20,208
Other	14,719		16,292
Total	$	278,262	$	297,867


(1)	As of June 30, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.